TP53 mutations are strong predictors of poor survival and refractoriness in chronic lymphocytic leukemia (CLL) and have direct implications for disease management. Clinical information on TP53 mutations is limited to lesions represented in >20% leukemic cells. Here, we tested the clinical impact and prediction of chemorefractoriness of very small TP53 mutated subclones. The TP53 gene underwent ultra-deep-next generation sequencing (NGS) in 309 newly diagnosed CLL. A robust bioinformatic algorithm was established for the highly sensitive detection of few TP53 mutated cells (down to 3 out of ∼1000 wild-type cells). Minor subclones were validated by independent approaches. Ultra-deep-NGS identified small TP53 mutated subclones in 28/309 (9%) untreated CLL that, due to their very low abundance (median allele frequency: 2.1%), were missed by Sanger sequencing. Patients harboring small TP53 mutated subclones showed the same clinical phenotype and poor survival (hazard ratio = 2.01; P = .0250) as those of patients carrying clonal TP53 lesions. By longitudinal analysis, small TP53 mutated subclones identified before treatment became the predominant population at the time of CLL relapse and anticipated the development of chemorefractoriness. This study provides a proof-of-principle that very minor leukemia subclones detected at diagnosis are an important driver of the subsequent disease course

Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia / Rossi, D; Khiabanian, H; Spina, V; Ciardullo, C; Bruscaggin, A; Famà, R; Rasi, S; Monti, S; Deambrogi, C; De Paoli, L; Wang, J; Gattei, V; Guarini, Anna; Foa, Roberto; Rabadan, R; Gaidano, G.. - In: BLOOD. - ISSN 0006-4971. - 123:14(2014), pp. 2139-2147. [10.1182/blood-2013-11-539726]

Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.

GUARINI, Anna;FOA, Roberto;
2014

Abstract

TP53 mutations are strong predictors of poor survival and refractoriness in chronic lymphocytic leukemia (CLL) and have direct implications for disease management. Clinical information on TP53 mutations is limited to lesions represented in >20% leukemic cells. Here, we tested the clinical impact and prediction of chemorefractoriness of very small TP53 mutated subclones. The TP53 gene underwent ultra-deep-next generation sequencing (NGS) in 309 newly diagnosed CLL. A robust bioinformatic algorithm was established for the highly sensitive detection of few TP53 mutated cells (down to 3 out of ∼1000 wild-type cells). Minor subclones were validated by independent approaches. Ultra-deep-NGS identified small TP53 mutated subclones in 28/309 (9%) untreated CLL that, due to their very low abundance (median allele frequency: 2.1%), were missed by Sanger sequencing. Patients harboring small TP53 mutated subclones showed the same clinical phenotype and poor survival (hazard ratio = 2.01; P = .0250) as those of patients carrying clonal TP53 lesions. By longitudinal analysis, small TP53 mutated subclones identified before treatment became the predominant population at the time of CLL relapse and anticipated the development of chemorefractoriness. This study provides a proof-of-principle that very minor leukemia subclones detected at diagnosis are an important driver of the subsequent disease course
2014
01 Pubblicazione su rivista::01a Articolo in rivista
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia / Rossi, D; Khiabanian, H; Spina, V; Ciardullo, C; Bruscaggin, A; Famà, R; Rasi, S; Monti, S; Deambrogi, C; De Paoli, L; Wang, J; Gattei, V; Guarini, Anna; Foa, Roberto; Rabadan, R; Gaidano, G.. - In: BLOOD. - ISSN 0006-4971. - 123:14(2014), pp. 2139-2147. [10.1182/blood-2013-11-539726]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/555112
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 121
  • Scopus 286
  • ???jsp.display-item.citation.isi??? 272
social impact